Log in | Register

Home
All Journals
Expert Opinion on Drug Safety
List of Issues
Volume 20, Issue 5

Expert Opinion on Drug Safety

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Register a free Taylor & Francis Online account today to boost your research and gain these benefits:

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Register now or learn more

Expert Opinion on Drug Safety, Volume 20, Issue 5 (2021)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Drug Safety, Volume 20, Issue 5 (2021)

See all volumes and issues

Vol 23, 2024 Vol 22, 2023 Vol 21, 2022 Volume 20, 2021 Vol 19, 2020 Vol 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Vol 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Editorial

Questions and facts regarding denosumab discontinuation among postmenopausal women

Polyzois Makras & Athanasios D. Anastasilakis

Pages: 499-501

Published online: 29 Dec 2020

First Page PreviewforQuestions and facts regarding denosumab discontinuation among postmenopausal women | Full Text | References | PDF (157 KB) | EPUB

1919 Views
0 CrossRef citations
0Altmetric

Free Access

Review

Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs

Elena Lorenzi, Matteo Simonelli, Pasquale Persico, Angelo Dipasquale & Armando Santoro

Pages: 503-521

Published online: 26 Feb 2021

AbstractforRisks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs | Full Text | References | PDF (471.3 KB) | EPUB

277 Views
6 CrossRef citations
0Altmetric

Safety considerations when using drugs in pregnant patients with systemic lupus erythematosus

Anna Viola Taulaigo, Liala Moschetti, Sara Ganhão, Maria-Chiara Gerardi, Franco Franceschini, Angela Tincani & Laura Andreoli

Pages: 523-536

Published online: 08 Mar 2021

AbstractforSafety considerations when using drugs in pregnant patients with systemic lupus erythematosus | Full Text | References | PDF (1.2 MB) | EPUB

323 Views
2 CrossRef citations
0Altmetric

Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors

Yuji Shibata, Shuji Murakami & Terufumi Kato

Pages: 537-547

Published online: 10 Mar 2021

AbstractforOverview of checkpoint inhibitor pneumonitis: incidence and associated risk factors | Full Text | References | PDF (395.6 KB) | EPUB

542 Views
7 CrossRef citations
0Altmetric

Safety of treatment options available for postoperative pain

Zhaosheng Jin, Christopher Lee, Kalissa Zhang, Tong J Gan & Sergio D Bergese

Pages: 549-559

Published online: 17 Mar 2021

AbstractforSafety of treatment options available for postoperative pain | Full Text | References | PDF (385.8 KB) | EPUB

312 Views
6 CrossRef citations
0Altmetric

Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome

Rima Nabbout, N Chemaly, C Chiron & M. Kuchenbuch

Pages: 561-576

Published online: 28 Feb 2021

AbstractforSafety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome | Full Text | References | PDF (2.1 MB) | EPUB

286 Views
0 CrossRef citations
0Altmetric

Systematic review and meta-analysis

Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis

Gonçalo Martins e Pereira, Gonçalo S. Duarte, Vasyl Katerenchuk, João Costa, Cláudio David, Joaquim J. Ferreira, Fausto J. Pinto & Daniel Caldeira

Pages: 577-588

Published online: 27 Jan 2021

470 Views
4 CrossRef citations
0Altmetric

Original Research

Article

Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies

Mina Tsurumi, Shinya Suzuki, Jiro Hokugo & Kazuo Ueda

Pages: 589-601

Published online: 10 Mar 2021

2806 Views
2 CrossRef citations
0Altmetric

Open Access

Article

Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)

Cong Bang Truong, Spencer H. Durham & Jingjing Qian

Pages: 603-609

Published online: 22 Feb 2021

AbstractforComparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS) | Full Text | References | PDF (862.9 KB) | EPUB

284 Views
4 CrossRef citations
0Altmetric

Article

Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?

Yusuf Acikgoz, Oznur Bal, Gokhan Ucar, Ayse Durnali, Yakup Ergun, Merve Dirikoc, Selin Akturk Esen & Mutlu Dogan

Pages: 611-621

Published online: 05 Mar 2021

AbstractforIs there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity? | Full Text | References | PDF (2.4 MB) | EPUB

146 Views
0 CrossRef citations
0Altmetric

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis

Rouhin Sen et al.

Review Article | Published online: 23 May 2024

Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis

Yi Zhao et al.

Article | Published online: 23 May 2024

Safety assessment of clomiphene: a real-world pharmacovigilance analysis from the Food and Drug Administration adverse event reporting system

Yifeng Shao et al.

Article | Published online: 23 May 2024

Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer

Man Xu et al.

Article | Published online: 22 May 2024

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Drug Safety (Vol.20, Iss.5, 2021)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?